Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C infection: eligibility for antiviral therapies.

European journal of gastroenterology & hepatology - 1 Nov 2005

Delwaide Jean, El Saouda Refaat, Gérard Christiane, Belaïche Jacques

Abstract excerpt

BACKGROUND: Current treatments of chronic hepatitis C virus (HCV) are effective, but expensive and susceptible to induce significant side effects. OBJECTIVES: To evaluate the proportion of HCV patients who are eligible for a treatment. METHODS: In a database comprising 1726 viraemic HCV patients, the files of 299 patients who presented to the same hepatologist for an initial appointment between 1996 and 2003 were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Contraindications
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Patient Selection

Share to Risk Factors

Share to Transaminases

Share to Treatment Outcome

Source

Identifiers

PMID: 16215430
DOI: 10.1097/00042737-200511000-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C infection: eligibility for antiviral therapies.PMID 16215430Read ↗

A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapiesSemantic proximity Read ↗

Current therapy for hepatitis C.Semantic proximity Read ↗

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Semantic proximity Read ↗

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.Semantic proximity Read ↗

[Difficult-to-treat patients with chronic hepatitis C].Semantic proximity Read ↗

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Semantic proximity Read ↗

Chronic hepatitis C treatment in näive patients.Semantic proximity Read ↗

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.Semantic proximity Read ↗

Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C.Semantic proximity Read ↗

Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center.Semantic proximity Read ↗

Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals.Semantic proximity Read ↗

Clinical outcomes in a cohort of anti-hepatitis C virus-positive patients with significant barriers to treatment referred to a Norwegian outpatient clinic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.